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Introduction
Anti-arrhythmic drugs are often prescribed for
pacemaker and implantable cardioverter-deﬁbrillator
(ICD) patients for a number of reasons. However, we
must be aware that anti-arrhythmic drugs may
inﬂuence pacing threshold and deﬁbrillation thresh-
old. Sometimes awareness on the part of the
physician is critical for patients with an implanted
pacemaker or an ICD.
I. Eﬀects of anti-arrhythmic drugs on pacing
threshold
Patients with implanted pacemakers often have
tachyarrhythmias, such as atrial ﬁbrillation. Anti-
arrhythmic drugs usually have bradycardiac ef-
fects.1–8) Pacemaker implantation allows the use of
anti-arrhythmic drugs for patients with bradycardia.
However, pacing threshold is sometimes increased
by the anti-arrhythmic drugs.
Factors aﬀecting pacing threshold are posture,
exercise, diet, sleep, minerals, pH, hormones, auto-
nomic tones, and underlying diseases.2) Type of
pacing leads9) and anti-arrhythmic drugs1–8) also
have great impacts on the pacing threshold.
Eﬀects of anti-arrhythmic drugs for pacing thresh-
old are shown in Figure 1. Eﬀects of anti-arrhythmic
drugs for pacing threshold are summarized as
follows;
‹ Vaughan Williams class Ia anti-arrhythmic
drugs may increase pacing threshold. However
the eﬀects are usually minimallittle.
› Class Ib anti-arrhythmic drugs have little
inﬂuence on pacing threshold.
ﬁ Class Ic anti-arrhythmic drugs have the stron-
gest eﬀects on increasing pacing threshold. It
may increase the pacing threshold up to ﬁve-
fold.
ﬂ Class II, III, IV anti-arrhythmic drugs have
little inﬂuence on pacing threshold.
A signiﬁcant positive correlation between prolon-
gation of QRS and increase of pacing threshold
under the use of propafenone has been reported8) and
class Ic anti-arrhythmic drugs have the strongest
eﬀects for increasing pacing threshold. Therefore,
increasing eﬀects of pacing threshold may be related
to suppression of _Vmax in phase 0 of the cardiac
muscle action potential. Pacing threshold is decreas-
ed by increasing sympathetic nervous tones and is
increased by increasing parasympathetic nervous
tones. Adverse eﬀects of class Ia anti-arrhythmic
drugs on pacing threshold may be suppressed by
anticholinergic eﬀect of class Ia anti-arrhythmic
drugs. Inﬂuences of anti-arrhythmic drugs are diﬀer-
ent patient to patient although the reasons are not
clear. Pacing threshold is dramatically increased by
anti-arrhythmic drugs in a particular patient; how-
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Anti-arrhythmic 
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qunidine
procainamide
ajimaline
disopyramide
cibenzoline
pirmenol
aprindine
lidocaine
phenytoin
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propafenone
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flecainide
propranolol
amiodarone
sotalol
verapamil
digitalis
: increase: no change, : decrease,
Figure 1 Eﬀects of anti-arrhythmic drugs for pacing thresh-
old
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ever, pacing threshold is not changed by anti-
arrhythmic drugs in other patients. As the pacing
output is usually set at more than twice the safety
margin, there is no problem if the increase of pacing
threshold is less than that level. However, when the
increase of pacing threshold is greater than twice,
pacing failure may occur.
Steroid-eluting electrodes suppress the increase of
pacing threshold after pacemaker implantation. One
report shows that steroid-eluting electrodes may
suppress the adverse eﬀect of anti-arrhythmic drugs
on the pacing threshold.9) However, these eﬀects still
remain unclear.
II. Eﬀects of anti-arrhythmic drugs on deﬁbrilla-
tion threshold (DFT)
ICD is highly eﬀective for lethal arrhythmia in
terms of improvements of survival rates. However,
ICD does not have suppressive eﬀects on the
incidence of ventricular tachycardia (VT) or ven-
tricular ﬁbrillation. Inappropriate shock is also a big
problem. Atrial ﬁbrillation is the one of the most
common reasons of inappropriate shock. Anti-
arrhythmic drugs are used for the suppression of
atrial ﬁbrillation. DC shock is very painful for
patients and both appropriate and inappropriate DC
shock may be suppressed by the use of anti-
arrhythmic drugs. Anti-arrhythmic drugs, especially
amiodarone, are often prescribed in ICD patients for
this reason. Intervals of VT are sometimes prolonged
by anti-arrhythmic drugs. Slowing the VT rates
sometimes makes detection of VT diﬃcult. More-
over, anti-arrhythmic drugs may have inﬂuences for
DFT.10–25) Cardioversion may fail if DFT increases
over the energy of DC setting.
Eﬀects of anti-arrhythmic drugs on the deﬁbrilla-
tion threshold (DFT) are shown in Table 1. As DFT
measurements may be diﬃcult, results are not same
in each report.10–25) Generally, Ikr blockers may
improve DFT,17–20) and Iks blockers may increase
DFT.10–12) Many anti-arrhythmic drugs such as
amiodarone (chronic phase),10–12) atropine,13) diltia-
zem,14) verapamil,15) and ﬂecainide,16) may increase
DFT. Disopyramide,12,23) procainamide.24) and prop-
afenone25) do not change DFT. However, opinions
diﬀer regarding this matter.
We should pay attention to amiodarone. Although
amiodarone can improve DFT in the acute phase (Ikr
blocking eﬀects are dominant), amiodarone increas-
es DFT in the chronic phase (Iks blocking eﬀects are
dominant). Fortunately, the OPTIC study showed
that there is little clinical impact on the deteriorated
eﬀects for DFT of amiodarine.26) Although amiodar-
one increased DFT, the eﬀect with modern ICD
systems is very small. Therefore, DFT reassessment
after the institution of antiarrhythmic drug therapy
with amiodarone may not be required routinely.
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